This study is testing an experimental oral drug called CVM-1118 for people with advanced neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to see if the drug can slow or stop the cancer from growing. Researchers will also closely monitor …
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC